AzTrials
AzTrials

Tooth HypersensitivityNCT04875000

Hypersensitivity and Color Changes of Bleached Teeth Using Different Remineralizing Agents

A study testing Remineralizing agent I application, Remineralizing agent II application and Remineralizing agent III application in people with Tooth Hypersensitivity, run by National Research Centre, Egypt at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this in vivo study is to evaluate the post-bleaching enamel hypersensitivity and the possible color changes following the application of arginine and nano-hydroxyapatite remineralizing solutions after enamel bleaching using an in-office chemical bleaching agent. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Tooth Hypersensitivity
What is being tested?
Remineralizing agent I application, Remineralizing agent II application and Remineralizing agent III application
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
1 siteEgypt
Study dates
20 Mar 2021to 20 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Participants of 18-55 years old
  • Participants with good general and oral health.
  • Participants did not undergo any bleaching procedure before.
  • Participants with caries-free maxillary six anterior teeth without any restorations.
  • Participants do not suffer of periodontal diseases.
  • Participants willing to assess and sign the informed consent form.

Who cannot join

  • Participants with anterior restorations.
  • Participants with dental prosthesis of the anterior teeth.
  • Participants with orthodontics brackets.
  • Participants with severe internal teeth discoloration as in cases of tetracycline stains, fluorosis or non-vital teeth.
  • Smoking participants.
  • Breastfeeding and pregnant women.
Show all 11Show fewer
  • Participants with gingival and bone recession.
  • Participants with dental erosion, dentin exposure, and cracked teeth or any other pathologic condition that may elicit teeth sensitivity.
  • Participants having their teeth bleached.
  • Participants taking analgesic or anti-inflammatory drugs.
  • Participants with bruxism habits are excluded from the study.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • National Research Centre

    Cairo, Giza Governorate, 12622

Other trials in Egypt

About this study

Official title: Effect of Arginine and Nano-hydroxyapatite Solutions on Hypersensitivity and Color Changes of Bleached Enamel: a Randomized Controlled Trial

The aim of this in vivo study is to evaluate the post-bleaching enamel hypersensitivity and the possible color changes following the application of arginine and nano-hydroxyapatite remineralizing solutions after enamel bleaching using an in-office chemical bleaching agent. A commercial Fluoride remineralizing and desensitizing agent will be used as the control group. Following bleaching of the anterior teeth and then the application of the different tested remineralizing agents; the patients will be assessed for post-bleaching hypersensitivity using the visual analogue scale (VAS) to describe the severity of the hypersensitivity from mild to moderate to severe. On the other hand, the baseline shade and post-bleaching color changes will be evaluated using a shade guide. The data will be collected and tabulated then the statistical analysis will be performed.

The null hypothesis is that the different tested remineralizing agents will have a similar effect on the post-bleaching teeth hypersensitivity \& the color changes of the bleached teeth.

Read the detailed description

Recently, there has been several patients that favor the in-office bleaching technique due to its quick and satisfying aesthetic outcome, nevertheless clinical research reported some clinical adverse effects. Teeth hypersensitivity is the most common adverse effect of teeth bleaching. It was suggested that hydrogen peroxide can pass to the pulp through enamel and dentin to create an inflammatory reaction or directly stimulate the neural receptors triggering pain sensation.

It was reported that tooth sensitivity during bleaching has a range of 18-78%. Usually, teeth hypersensitivity subsides upon accomplishment of the bleaching procedure, but occasionally it may cause the patient to withdraw from form the treatment session. Different methods and approaches with a varying rate of success have been advocated to reduce teeth sensitivity, such as decreasing the rate of application, using different desensitizing agents before or after bleaching procedure, desensitizing agent incorporation into the bleaching gel, and decreasing the concentration of bleaching agent. In this context, the efficacy of desensitizing obliteration agents to prevent and treat the post-bleaching hypersensitivity has been investigated in many clinical trials presenting promising results. These obliterating agents can enhance the enamel mineral content, impeding hydrogen peroxide infiltration to the nerve endings and thereby hypersensitivity is much reduced or even eliminated.

Study design:

This randomized clinical study will use the "excel sheet" for randomization and assigning the subjects into the respective test groups.

All the included subjects will sign an informed consent before participating in this clinical study, in full accordance with the World Medical Association Declaration of Helsinki.

Settings and locations:

From the pre-determined inclusion and exclusion criteria, a total of 33 volunteers will be enrolled for the study. The clinical study will be performed from March 2021, through June 2021, in the outpatient dental clinic at the National Research Centre in Egypt.

Sample size calculation:

An equivalence test of means using two one-sided tests based on data from a previous study resulted in a design of 11 patient in each group (control and treatment groups) as minimum sample sizes and will achieves 92% power at a 5.0% significance level when the true difference between the Visual Analogue Scale (VAS) means is 0.3, the standard deviation is 0.3, and the equivalence limits are -0.7 and 0.7.

Tested materials:

The materials to be used in the study will be: an in-office hydrogen peroxide chemical-activated bleaching kit: Opalescence™ Boost™ 40% hydrogen peroxide Tooth Whitening System (Ultradent Products, Inc., South Jordan, UT, USA) and three desensitizing agents: a commercially available UltraEZ desensitizing gel (Ultradent Products, Inc., South Jordan, UT, USA) and 2.5% concentration of arginine and nano-Hydroxy apatite solutions.

Sample grouping:

The enrolled 33 participants will be randomly divided into three groups (n=11) according to the "Coin-Toss method", representing the investigated remineralizing and desensitizing agent to be received after bleaching of their maxillary and mandibular anterior teeth with a 40% hydrogen peroxide in-office chemical-activated bleaching agent as follows:

Group I : UltraEZ desensitizing gel application after bleaching (control). Group II : 2.5% Arginine solution application after bleaching. Group III: 2.5% nano-hydroxyapatite solution application after bleaching.

In-office teeth bleaching:

Pre-operative hypersensitivity will be determined and recorded for all enrolled subjects using the VAS method.

Baseline shade color of the predetermined teeth will be recorded using Classical VITAPAN shade guide.

The in-office bleaching procedure will be performed using Opalescence™ Boost™ 40% Tooth Whitening System (Ultradent Products, Inc., South Jordan, Utah, USA) chemical bleaching agent according to the manufacturer instructions.

Preparation of arginine and nano-hydroxyapatite solutions:

Two and a half g of arginine powder (Sigma-Aldrich, St. Louis, MO, USA), and 2.5 g of nano-hydroxyapatite powder (Sigma-Aldrich, St. Louis, MO, USA) will be weighed with a digital balance then mixed with 100 ml of distilled water to obtain a 2.5%-concentration of arginine and nano-hydroxyapatite solutions.

Application of the remineralizing agents:

A commercially available fluoride agent "UltraEZ gel (Ultradent Products, Inc., South Jordan, UT, USA)" will be applied to the teeth of the assigned patients of Group I and left undisturbed for 20 min as recommended by the manufacturer. Then the patients will be instructed to rinse their teeth thoroughly with water. The 2.5% prepared solutions of arginine and nano-hydroxyapatite will be applied to the bleached teeth of the assigned patients of Group II and Group III respectively, using micro brushes in a generous amount to the labial surfaces of the bleached teeth and left undisturbed for 20 min. Then the patients will be instructed to rinse their teeth thoroughly with water.

Post-operative hypersensitivity evaluation:

The post-operative hypersensitivity of the bleached maxillary anterior teeth will be recorded immediately after bleaching then once again after application of the remineralizing agents at the same session. Tooth sensitivity will be evaluated using a 3-way syringe at 5 to 10 cm distance using the Visual Analogue Scale (VAS). Whereby, readings from 0-10. Zero denoting no sensitivity, 1-3 is presented as mild, 4-7 is presented as moderate and 8-10 is presented as severe sensitivity. After that, it will be recorded on daily bases for the first week by the participants who will be asked to bring their records in the follow-up sessions. Then the postoperative hypersensitivity will be evaluated in-office every week for a 3-week follow-up period using the VAS scoring system. All the readings will be recorded in a self-structured proforma.

Post-operative color evaluation:

The post-bleaching shades of the maxillary anterior teeth will be recorded immediately after bleaching, then once again after application of the desensitizing agents at the same session. Afterwards, it will be recorded every week for a 3-week follow-up period using VITAPAN classical A1-D4® shade guide at the middle third of the anterior maxillary teeth. The 16 tabs of the VITAPAN classical shade guide were arranged in descending numerical order regarding the value from B1 to C4. Then these values were converted into code numbers using a conversion table.

Being tested
Remineralizing agent I application, Remineralizing agent II application, Remineralizing agent III application
Keywords
Teeth bleaching, Remineralizing agents, Arginine solution, Nano-hydroxyapatite solution, Hypersensitivity, Color changes
Medical subject headings
Dentin Sensitivity, Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Remineralizing agent I applicationOther

    Application of UltraEZ remineralizing agent to the bleached teeth

  • Remineralizing agent II applicationOther

    Application of 2.5% arginine solution to the bleached teeth

  • Remineralizing agent III applicationOther

    Application of 2.5% nano-hydroxyapatite solution to the bleached teeth

Study groups in NCT04875000
Study groupRoleWhat they receive
UltraEZActive comparatorGroup of patients randomly assigned to receive the the application of the commercial fluoride remineralizing and desensitizing agent "UltraEZ (Ultradent Products, Inc, South Jordan, UT, USA)" after teeth bleaching
Receives: Other: Remineralizing agent I application
ArginineExperimentalGroup of patients randomly assigned to receive the the application of the 2.5% arginine solution after teeth bleaching
Receives: Other: Remineralizing agent II application
Nano-hydroxyapatiteExperimentalGroup of patients randomly assigned to receive the application of the 2.5% nano-hydroxyapatite solution after teeth bleaching
Receives: Other: Remineralizing agent III application

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Teeth Hypersensitivity change

    Evaluation of the change in the pre- and post-bleaching teeth hypersensitivity using the Visual Analogue Scale method (VAS) to describe the severity of the hypersensitivity from mild to moderate to severe. Whereby, readings from 0-10. Zero denoting no sensitivity, 1-3 is presented as mild, 4-7 is presented as moderate and 8-10 is presented as severe sensitivity by the description of each one of the participants using a printed chart.

    Measured: Baseline to 3-week follow up period.

Secondary outcomes (1)
  1. Color change

    Evaluation of the pre- and post-bleaching teeth color change using the VITA classical shade guide at the middle third of the anterior maxillary teeth. The 16 tabs of the VITAPAN classical shade guide will be arranged in descending numerical order regarding the value from B1 to C4. These values will be converted into code numbers using a conversion table.

    Measured: Baseline to 3-week follow up period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2021
  2. Study start20 Mar 2021
  3. Primary completion20 Jun 2021
  4. Study completion20 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Parallel interventional study model
Masking
Single blind
Who is masked
Participant
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04875000
Sponsor's protocol ID
2433042021
Status last verified
Apr 2021
First submitted
24 Apr 2021
Last updated
28 Jun 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Soares DG, Basso FG, Pontes EC, Garcia Lda F, Hebling J, de Souza Costa CA. Effective tooth-bleaching protocols capable of reducing H(2)O(2) diffusion through enamel and dentine. J Dent. 2014 Mar;42(3):351-8. doi: 10.1016/j.jdent.2013.09.001. Epub 2013 Sep 19.

    PubMed 24056046
  • Browning WD, Chan DC, Myers ML, Brackett WW, Brackett MG, Pashley DH. Comparison of traditional and low sensitivity whiteners. Oper Dent. 2008 Jul-Aug;33(4):379-85. doi: 10.2341/07-134.

    PubMed 18666494
  • Cardoso PC, Reis A, Loguercio A, Vieira LC, Baratieri LN. Clinical effectiveness and tooth sensitivity associated with different bleaching times for a 10 percent carbamide peroxide gel. J Am Dent Assoc. 2010 Oct;141(10):1213-20. doi: 10.14219/jada.archive.2010.0048.

    PubMed 20884923
  • Pintado-Palomino K, Peitl Filho O, Zanotto ED, Tirapelli C. A clinical, randomized, controlled study on the use of desensitizing agents during tooth bleaching. J Dent. 2015 Sep;43(9):1099-1105. doi: 10.1016/j.jdent.2015.07.002. Epub 2015 Jul 6.

    PubMed 26159384
  • Borges BC, Borges JS, de Melo CD, Pinheiro IV, Santos AJ, Braz R, Montes MA. Efficacy of a novel at-home bleaching technique with carbamide peroxides modified by CPP-ACP and its effect on the microhardness of bleached enamel. Oper Dent. 2011 Sep-Oct;36(5):521-8. doi: 10.2341/11-013-L. Epub 2011 Aug 5.

    PubMed 21819199

Questions about this trial

What is this clinical trial studying?

A study testing Remineralizing agent I application, Remineralizing agent II application and Remineralizing agent III application in people with Tooth Hypersensitivity, run by National Research Centre, Egypt at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Teeth Hypersensitivity change (time frame: Baseline to 3-week follow up period.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04875000, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in